人乳头瘤病毒预防性疫苗的研究进展和应用现状  

Review for progress and current status of human papillomavirus prophylactic vaccine

作　　者：李韵冰 宋硕[1] 王大宁[2] 李智海[1] 夏宁邵[1,2] 李少伟[1,2] 

机构地区：[1]厦门大学国家传染病诊断试剂与疫苗工程技术研究中心生命科学学院,厦门361102 [2]厦门大学分子疫苗学与分子诊断学国家重点实验室公共卫生学院,厦门361102

出　　处：《中国生化药物杂志》2016年第6期33-37,共5页Chinese Journal of Biochemical Pharmaceutics

摘　　要：高危型人乳头瘤病毒(human papilloma virus,HPV)感染被证实是诱发女性宫颈癌的主要原因。宫颈癌已成为继乳腺癌之后世界范围内严重威胁妇女健康的疾病。目前宫颈癌治疗效果不佳,因此预防HPV感染尤为重要。国外已上市的3种HPV预防性疫苗显示出良好的安全性和有效性,但由于生产成本和售价较高,阻碍了其在发展中国家和经济较落后的地区推广应用。目前,这些疫苗尚未在我国上市,本文综述了HPV疫苗的研究进展和应用现状,为即将在我国上市的HPV疫苗提供信息。Persistant infection of high-risk human papillomavirus（ HPV） is the primary cause leading to cervical cancer,which is ranked as second cancer threatening the health of women following breast cancer. Development of HPV vaccine is very important because there is no effective therapeutics for cervical cancer. Three currently licensed HPV vaccines based on major capsid protein L1 in the foreign market confered good safety and efficacy in clinical trials,but the current price is expensive due to high cost,which limits the wide application in developing countries. So far,the vaccines have not been launced in China market. Here,we review the progress and the current status of the HPV vaccine,which will attract the readers＇ interest on the forthcoming emergence of HPV vaccine in China.

关 键 词：人乳头瘤病毒 主要衣壳蛋白L1 宫颈癌 疫苗 

分 类 号：R752.53[医药卫生—皮肤病学与性病学] R737.33[医药卫生—临床医学]